Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | BLM | P54132 | 2/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4212860 | 1.00 | KDM4E (0.57) | KDM4EKMT2AMAPTLMNATSHR | |
| SCHEMBL838982 | 0.95 | KDM4E (0.59) | KDM4EKMT2AMAPTLMNATSHR | |
| Benzene SCHEMBL28112748 | 0.95 | KDM4E (0.59) | KDM4EKMT2AMAPTLMNATSHR | |
| SCHEMBL18029023 | 0.95 | KDM4E (0.59) | KDM4EKMT2AMAPTLMNATSHR | |
| SCHEMBL1461102 | 0.95 | KDM4E (0.59) | KDM4EKMT2AMAPTLMNATSHR | |
| SCHEMBL29982303 | 0.95 | KDM4E (0.59) | KDM4EKMT2AMAPTLMNATSHR | |
| SCHEMBL1460647 | 0.90 | MAPT (0.69) | KDM4EKMT2AMAPTLMNATSHR | |
| SCHEMBL1460650 | 0.90 | MAPT (0.69) | KDM4EKMT2AMAPTLMNATSHR | |
| SCHEMBL18029110 | 0.90 | MAPT (0.69) | KDM4EKMT2AMAPTLMNATSHR | |
| SCHEMBL4212849 | 0.88 | KDM4E (0.52) | KDM4EKMT2AMAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10716778-B2 | Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals | Veijlen (CW) | 2020-07-21 | — | — | US | disclosed |
| US-20160331725-A1 | USE OF COMPOUNDS THAT ARE ABLE TO INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASE STATES ASSOCIATED WITH A REDUCED IGF-1 SERUM LEVEL IN HUMANS AND ANIMALS | VEIJLEN N.V. | 2016-11-17 | — | — | US | disclosed |
| US-9408405-B2 | Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals | VEIJLEN N.V. (CW) | 2016-08-09 | — | — | US | disclosed |
| US-20090028796-A1 | PESTICIDAL COMPOSITION COMPRISING INDOLE DERIVATES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) | 2009-01-29 | — | — | US | disclosed |
| EP-1978805-A1 | PESTICIDAL COMPOSITION COMPRISING INDOLE DERIVATES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-20080194553-A1 | compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition,in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome | VEIJLEN N.V. (NL) | 2008-08-14 | — | — | US | disclosed |
| WO-2007085660-A1 | PESTICIDAL COMPOSITION COMPRISING INDOLE DERIVATES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2007-08-02 | — | — | WO | disclosed |
| EP-1670444-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | Veijlen N.V. (AN) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005039546-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | VEIJLEN N.V. (AN) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028796-A1 | PESTICIDAL COMPOSITION COMPRISING INDOLE DERIVATES | IDO1, IDO2, INMT | KDM4E 2045/4885KMT2A 3257/4885MAPT 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.